What caused the intraday spike in ALNA stock volume on 22 Jan 2026?

The intraday spike to **252,311,606.00** shares likely reflects a mix of speculation, short-term trading, and market chatter about potential NASDAQ delisting. Public coverage, including [MarketBeat](https://www.marketbeat.com/stocks/NASDAQ/ALNA/), increased attention and amplified volatility in ALNA

What are the key fundamentals to watch for ALNA stock?

Watch cash per share **$0.92**, EPS **-0.64**, book value per share **$0.58**, and NASDAQ listing status. Clinical progress for ALLN-346 and any capital raises will materially affect ALNA stock

What is Meyka AI’s forecast for ALNA stock?

Meyka AI's forecast model projects a base-case **$0.12**, bull **$0.30**, and bear **$0.03**, compared with the current trade **USD 0.075**. Forecasts are model-based projections and not guarantees

Is ALNA stock suitable for long-term portfolios?

Given ALNA stock’s low price, negative EPS, and listing risk, it is generally unsuitable for conservative long-term portfolios. Only experienced investors who accept high volatility and illiquidity should consider small, speculative positions

US Stocks

ALNA Allena Pharmaceuticals NASDAQ 22 Jan 2026: 252,311,606 shares, liquidity signal

ByDanny Kontos January 22, 2026January 22, 2026

ALNA stock moved on heavy volume intraday on 22 Jan 2026 after 252,311,606.00 shares changed hands on the NASDAQ in the United States. The ticker printed $0.075 at the trade print, a 3.16% intraday rise from the prior close, and a trading range between $0.06 and $0.15. That surge in activity coincides with market chatter about potential delisting and has amplified price swings for Allena Pharmaceuticals, Inc. (NASDAQ: ALNA). We look at the drivers, financials, technicals, and a concise forecast to frame the near-term opportunity and risk for ALNA stock.